Alpha Cognition Inc. announced plans to deliver three presentations at the 2025 Alzheimer’s Association International Conference (AAIC), scheduled for July 27–31, 2025, in Toronto, Canada. These presentations will highlight clinical studies supporting ZUNVEYL.
The studies demonstrated bioequivalence to galantamine immediate-release and extended-release formulations, which were integral to the New Drug Application submission and approval. Showcasing this data at a prominent conference underscores ZUNVEYL's scientific validation.
The company believes these presentations will emphasize ZUNVEYL’s potential to provide meaningful clinical benefits to patients. This engagement with the scientific community is crucial for establishing ZUNVEYL as an attractive new option for Alzheimer’s disease patients and caregivers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.